NantHealth, Inc.

Q3 2022 total revenue was $16.6 million, up from $14.4 million in Q3 2021. Gross profit was $9.7 million versus $7.5 million last year, and gross margin was 58% versus 52% last year. Net loss attributable to NantHealth was $13.7 million, or $0.12 per share, compared with $10.8 million, or $0.09 per share in the prior-year quarter. On a non-GAAP basis, net loss from continuing operations was $14 million, or $0.12 per share, versus $11.5 million, or $0.10 per share a year ago. Year-to-date revenue was $49.5 million versus $46.6 million last year, and year-to-date gross margin was up approximately 9% year over year. Management did not provide formal next-quarter or full-year guidance on the call.

Ron Louks struck an upbeat tone, emphasizing that the company has generated positive momentum over several quarters and that broadening product offerings for existing customers is paying off. He highlighted contract renewals, added products and services, URAC accreditation for Eviti Connect through 2025, and new functionality intended to reduce manual work and speed care decisions. His commentary focused on execution and commercial traction rather than on financial outlook.

Bob Petrou walked through the quarter’s financials and pointed to revenue growth, with Q3 revenue at $16.6 million and year-to-date revenue at $49.5 million, up about 6% year over year. He highlighted gross profit of $9.7 million and gross margin of 58%, up from 52% last year, while noting operating expenses rose to $23.9 million and year-to-date operating expenses were up about 21.2% due to continued investment in product portfolios and technology build-out. He also said cash and cash equivalents were approximately $0.6 million at September 30, down from $5.7 million at June 30, and cash usage of about $5.1 million was driven by normal working capital needs.

There was no substantive analyst Q&A in the transcript, so no management responses to outside questions were provided. The only discussion was the prepared remarks, which covered revenue growth, margin improvement, renewals, and the cash balance. As a result, there were no additional concerns or clarifications raised on the call.